Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK1 Inhibition in Granuloma Annulare
NCT05650736Phase 2Completed
- Start
- Oct 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abrocitinib in granuloma annulare (GA). Started Oct 2023; status: completed.
02
Drugs
abrocitinib
03
Conditions
granuloma annulare (GA)
Beyond the preview
Go deeper on NCT05650736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05650736.